98%
921
2 minutes
20
Background: Patients with complex coronary artery disease, as defined by high SYNTAX scores, undergoing percutaneous coronary intervention (PCI) have poorer outcomes when compared with patients with lower SYNTAX I scores. This study aimed to assess if mechanical circulatory support using Impella mitigates the effect of the SYNTAX I score on outcomes after high-risk percutaneous coronary intervention (HRPCI).
Methods: Using data from the PROTECT III study, patients undergoing Impella-assisted HRPCI between March 2017 and March 2020 were divided into 3 cohorts based on SYNTAX I score-low (≤22), intermediate (23-32), and high (≥33). Procedural and clinical outcomes out to 90 days were compared between groups. Multivariable regression analysis was used to assess the impact of SYNTAX I score on major adverse cardiovascular and cerebrovascular events (MACCE) at 90 days.
Results: A total of 850 subjects with core laboratory-adjudicated SYNTAX I scores were identified (low: n = 310; intermediate: n = 256; high: n = 284). Patients with high SYNTAX I scores were older than those with low or intermediate SYNTAX I scores (72.7 vs 69.7 vs 70.1 years, respectively; < .01). After adjustment for covariates, high SYNTAX I score remained a significant predictor of 90-day MACCE (hazard ratio [HR], 2.14; 95% CI, 1.42-3.69; < .01 vs low), whereas intermediate SYNTAX I score was not (HR, 0.92; 95% CI, 0.47-1.77; = .80 vs low). These findings persisted after adjustment for post-PCI SYNTAX I score.
Conclusions: A high SYNTAX I score was associated with higher rates of 90-day MACCE in patients who underwent Impella-assisted HRPCI. Further research is needed to understand the patient and procedural factors driving this finding.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11330901 | PMC |
http://dx.doi.org/10.1016/j.jscai.2024.101981 | DOI Listing |
J Behav Med
September 2025
Department of Psychology, University of Wisconsin-La Crosse, La Crosse, WI, USA.
Latent profile analysis (LPA) is in the finite mixture model analysis family and identifies subgroups by participants' responses to continuous variables (i.e., indicators); participants' probable membership in each subgroup is based on the similarity between the subgroup's prototypical responses and the person's unique responses.
View Article and Find Full Text PDFCardiovasc Interv Ther
September 2025
Division of Cardiovascular Medicine, Toyohashi Heart Center, Aichi, Japan.
The outcome of percutaneous coronary intervention (PCI) compared to coronary artery bypass grafting (CABG) is still controversial for patients with left main coronary artery (LMCA) disease. This multicenter cohort study aimed to evaluate the clinical outcomes of LMCA disease patients who underwent PCI or CABG. We reviewed 875 consecutive patients diagnosed with LMCA disease between January 2009 and December 2020 who underwent coronary revascularization by PCI (n = 404) or CABG (n = 471).
View Article and Find Full Text PDFFront Cardiovasc Med
August 2025
Pernambuco Cardiac Emergency Hospital, University of Pernambuco (PROCAPE, UPE), Recife, Brazil.
Atherosclerosis is the most important etiology of acute myocardial infarction, which is considered an inflammatory disease with specific cellular and molecular responses. Recent research has linked hematological variables as biomarkers of the severity of coronary artery disease. Studies suggest that nucleated red blood cells (NRBCs), neutrophil to lymphocyte ratio (NLR), and mean platelet volume (MPV) may serve as components of a laboratory model or hematological scoring system for in-hospital surveillance.
View Article and Find Full Text PDFCardiol J
September 2025
Department Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Education Research Hospital, University of Health Sciences, Istanbul, Türkiye.
Background: The aim of this study was to investigate whether serum uric acid to serum creatinine ratio (SUA/SCr) predicts the early major adverse cardiovascular and cerebrovascular events (MACCEs) in patients with ST elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVCAD).
Methods: This study was designed retrospectively and included 572 patients with a mean age of 61.9 ± 12.
Background: In the presence of a potent P2Yinhibitor such as prasugrel, the additional clinical antithrombotic benefit of aspirin is unclear. The feasibility of prasugrel monotherapy without aspirin after percutaneous coronary intervention (PCI) has been demonstrated in chronic coronary syndrome, but is yet to be assessed in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) and low anatomical complexity.
Methods And Results: ASET-Japan is a single-arm study investigating the safety of prasugrel 12-month monotherapy with a locally approved dose (loading 20 mg; maintenance 3.